In 2020, tazemetostat, a selective EZH2 inhibitor, was approved by the US Food and Drug Administration (FDA) to treat patients with epithelioid sarcoma and refractory follicular lymphoma [27]. Here, EZH2 is linked to follicular lymphoma.